Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Long-term exposure to oral methylphenidate or dl-amphetamine mixture in peri-adolescent rhesus monkeys: effects on physiology, behavior, and dopamine system development.

Soto PL, Wilcox KM, Zhou Y, Kumar A, Ator NA, Riddle MA, Wong DF, Weed MR.

Neuropsychopharmacology. 2012 Nov;37(12):2566-79. doi: 10.1038/npp.2012.119. Epub 2012 Jul 18. Erratum in: Neuropsychopharmacology. 2013 May;38(6):1141. Kumar, Anil [added].

2.

Chronic treatment with extended release methylphenidate does not alter dopamine systems or increase vulnerability for cocaine self-administration: a study in nonhuman primates.

Gill KE, Pierre PJ, Daunais J, Bennett AJ, Martelle S, Gage HD, Swanson JM, Nader MA, Porrino LJ.

Neuropsychopharmacology. 2012 Nov;37(12):2555-65. doi: 10.1038/npp.2012.117. Epub 2012 Jul 18.

3.

Long-term safety of stimulant use for ADHD: findings from nonhuman primates.

Volkow ND.

Neuropsychopharmacology. 2012 Nov;37(12):2551-2. doi: 10.1038/npp.2012.127. No abstract available.

4.

Imaging nicotine- and amphetamine-induced dopamine release in rhesus monkeys with [(11)C]PHNO vs [(11)C]raclopride PET.

Gallezot JD, Kloczynski T, Weinzimmer D, Labaree D, Zheng MQ, Lim K, Rabiner EA, Ridler K, Pittman B, Huang Y, Carson RE, Morris ED, Cosgrove KP.

Neuropsychopharmacology. 2014 Mar;39(4):866-74. doi: 10.1038/npp.2013.286. Epub 2013 Oct 15.

5.

Critical role of the embryonic mid-hindbrain organizer in the behavioral response to amphetamine and methylphenidate.

Tilleman H, Kofman O, Nashelsky L, Livneh U, Roz N, Sillaber I, Biegon A, Rehavi M, Brodski C.

Neuroscience. 2009 Nov 10;163(4):1012-23. doi: 10.1016/j.neuroscience.2009.07.040. Epub 2009 Jul 24.

6.

Effects of chronic oral methylphenidate on cocaine self-administration and striatal dopamine D2 receptors in rodents.

Thanos PK, Michaelides M, Benveniste H, Wang GJ, Volkow ND.

Pharmacol Biochem Behav. 2007 Oct;87(4):426-33. Epub 2007 Jun 5.

PMID:
17599397
8.

Sensitized nucleus accumbens dopamine terminal responses to methylphenidate and dopamine transporter releasers after intermittent-access self-administration.

Calipari ES, Jones SR.

Neuropharmacology. 2014 Jul;82:1-10. doi: 10.1016/j.neuropharm.2014.02.021. Epub 2014 Mar 13.

9.

Dynamic changes in sensitivity occur during the acute response to cocaine and methylphenidate.

Kuczenski R, Segal DS.

Psychopharmacology (Berl). 1999 Nov;147(1):96-103.

PMID:
10591874
10.

Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder.

Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, Logan J, Ma Y, Schulz K, Pradhan K, Wong C, Swanson JM.

Arch Gen Psychiatry. 2007 Aug;64(8):932-40.

PMID:
17679638
12.

The effects of chronic methylphenidate administration on operant test battery performance in juvenile rhesus monkeys.

Rodriguez JS, Morris SM, Hotchkiss CE, Doerge DR, Allen RR, Mattison DR, Paule MG.

Neurotoxicol Teratol. 2010 Mar-Apr;32(2):142-51. doi: 10.1016/j.ntt.2009.08.011. Epub 2009 Sep 6.

13.

Anti-hyperactivity medication: methylphenidate and amphetamine.

Seeman P, Madras BK.

Mol Psychiatry. 1998 Sep;3(5):386-96. Review.

PMID:
9774771
14.

The effects of adolescent methylphenidate self-administration on responding for a conditioned reward, amphetamine-induced locomotor activity, and neuronal activation.

Burton CL, Nobrega JN, Fletcher PJ.

Psychopharmacology (Berl). 2010 Feb;208(3):455-68. doi: 10.1007/s00213-009-1745-7. Epub 2009 Dec 18.

PMID:
20020108
15.

Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men.

Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M, Benkelfat C.

Arch Gen Psychiatry. 2006 Dec;63(12):1386-95.

PMID:
17146013
16.
17.

Impact of early life stress on the reinforcing and behavioral-stimulant effects of psychostimulants in rhesus monkeys.

Ewing Corcoran SB, Howell LL.

Behav Pharmacol. 2010 Feb;21(1):69-76. doi: 10.1097/FBP.0b013e3283359f53.

18.

Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies.

Koochesfahani KM, de la Fuente-Fernández R, Sossi V, Schulzer M, Yatham LN, Ruth TJ, Blinder S, Stoessl AJ.

Mov Disord. 2006 Jul;21(7):970-5.

PMID:
16570297
19.

Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine.

Schiffer WK, Volkow ND, Fowler JS, Alexoff DL, Logan J, Dewey SL.

Synapse. 2006 Mar 15;59(4):243-51.

PMID:
16385551
20.

Dopamine-related genotypes and the dose-response effect of methylphenidate on eating in attention-deficit/hyperactivity disorder youths.

Leddy JJ, Waxmonsky JG, Salis RJ, Paluch RA, Gnagy EM, Mahaney P, Erbe R, Pelham WE, Epstein LH.

J Child Adolesc Psychopharmacol. 2009 Apr;19(2):127-36. doi: 10.1089/cap.2008.046.

PMID:
19364291

Supplemental Content

Support Center